ストックスクリーナーアプリを入手
1.65
3.12%
0.05
アフターアワーズ：
1.72
0.07
+4.24%
前日終値:
$1.60
開ける：
$1.59
24時間の取引高:
3.09M
Relative Volume:
1.88
時価総額：
$368.39M
収益：
-
当期純損益:
$-283.26M
株価収益率:
-0.873
EPS:
-1.89
ネットキャッシュフロー:
$-273.61M
1週間 パフォーマンス:
-12.70%
1か月 パフォーマンス:
-34.78%
6か月 パフォーマンス:
-68.45%
1年 パフォーマンス:
-59.76%
1日の値動き範囲:
$1.55
$1.72
1週間の範囲:
$1.55
$2.07
52週間の値動き範囲:
$1.55
$12.00
Sana Biotechnology Inc Stock (SANA) Company Profile
名前
Sana Biotechnology Inc
セクター
電話
(206) 701-7914
住所
188 EAST BLAINE STREET, SUITE 400, SEATTLE
SANA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
1.65 | 368.39M | 0 | -283.26M | -273.61M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-05 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | 開始されました | Rodman & Renshaw | Buy |
| 2024-01-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-09-05 | 開始されました | Citigroup | Buy |
| 2023-08-14 | 開始されました | TD Cowen | Market Perform |
| 2023-05-02 | 開始されました | H.C. Wainwright | Neutral |
| 2021-03-01 | 開始されました | BofA Securities | Buy |
| 2021-03-01 | 開始されました | Goldman | Neutral |
| 2021-03-01 | 開始されました | JP Morgan | Neutral |
| 2021-03-01 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Sana Biotechnology Inc (SANA) 最新ニュース
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana Biotechnology stock hits 52-week low at $1.8 amid downturn - Investing.com Canada
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
Sana Biotechnology's SWOT analysis: cell therapy stock faces pivotal year ahead - Investing.com Canada
Sana Biotechnology stock hits 52-week low at $2.29 By Investing.com - Investing.com Canada
Sana Biotechnology stock hits 52-week low at $2.29 - Investing.com
Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus - Seeking Alpha
Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Bought by Fmr LLC - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc.SANA - PR Newswire
Sana Biotechnology Gets FDA Fast Track Designation for SC291 Cell Therapy - MarketWatch
Sana Biotechnology announces Fast Track designation for SC291 - TipRanks
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic - The Bakersfield Californian
Sana Biotechnology Announces Fast Track Designation for - GlobeNewswire
Sana Biotechnology (NASDAQ:SANA) Trading 9.8% HigherStill a Buy? - MarketBeat
Sana Biotechnology's (SANA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Sana Biotechnology to Present at December 2024 Investor Conferences - The Manila Times
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies - Quantisnow
Sana Biotechnology: The Story Becomes Murkier (NASDAQ:SANA) - Seeking Alpha
Sana Biotechnology (NASDAQ:SANA) Sets New 12-Month LowShould You Sell? - MarketBeat
10 Stocks Jeff Bezos Is Buying | Investing - U.S News & World Report Money
Sana Biotechnology's SWOT analysis: stock outlook amid strategic pivot - Investing.com India
Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio - Quantisnow
Sana Biotechnology, Inc. (NASDAQ:SANA) Holdings Lowered by Baillie Gifford & Co. - MarketBeat
Sana Biotechnology stock hits 52-week low at $2.75 By Investing.com - Investing.com Australia
FMR LLC's Strategic Acquisition of Sana Biotechnology Inc Shares - GuruFocus.com
Sana Biotechnology stock hits 52-week low at $2.75 - Investing.com India
Sana Biotech sustains stock target with Buy rating on Q3 earnings - Investing.com Nigeria
Analyst keeps Buy on Sana Biotechnology, adjusts outlook as blood cancer competition rises - Investing.com Canada
Sana Biotechnology's SWOT analysis: stock outlook amid strategic pivot By Investing.com - Investing.com Nigeria
Sana Biotechnology (NASDAQ:SANA) Hits New 1-Year LowWhat's Next? - MarketBeat
Sana Biotechnology Inc Still Hasn’t Convinced Analysts? - Stocks Register
HC Wainwright Reaffirms "Buy" Rating for Sana Biotechnology (NASDAQ:SANA) - MarketBeat
Sana Biotechnology downgraded to Market Perform from Outperform at JMP Securities - MSN
Sana Biotechnology, Inc. Reports Q3 2024 Financial Results - TipRanks
Sana: Q3 Earnings Snapshot - The Washington Post
Sana Biotechnology Inc. (SANA) Quarterly 10-Q Report - Quartzy
Earnings Flash (SANA) SANA BIOTECHNOLOGY Reports Q3 Loss $-0.27 Per Share - Marketscreener.com
Sana Biotechnology Inc (SANA) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):